Safety and Tolerability of the Glutamate Antagonist CGS 19755 (Selfotel) in Patients With Acute Ischemic Stroke

Completed

Phase 2 Results

Summary of Purpose

To evaluate the safety and tolerability of CGS 19755 and obtain pharmacokinetic and preliminary data on its efficacious dose range in patients treated within 12 hours of hemispheric ischemic stroke.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 10 December 2001.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • CIBA-GEIGY Corporation

Trial Design

Randomized, double-blind, placebo-controlled, ascending-dose phase IIa trial of 32 patients at 7 centers.

Contacts

Not available